Tag:
Ardea BioSciences
Latest Headlines
Latest Headlines
AstraZeneca plots more pipeline deals
Caught with one of the weakest late-stage programs in Big Pharma, promising drugs that can add some excitement and get the analysts to back off are welcome.
AstraZeneca reels in promising PhIII gout drug in $1.26B Ardea buyout
Hounded by a group of critics demanding a better pipeline strategy, AstraZeneca this morning wrapped a deal to buy Ardea Biosciences.
Ardea's Phase II gout drug shows promise
San Diego-based Ardea Biosciences has unveiled promising Phase II results from a trial of its oral gout drug RDEA594. When combined with the standard treatment allopurinol, 89 percent of patients
Ardea shares spike on promising PhIIb gout drug data
Shares of Ardea Biosciences ( RDEA ) surged 23 percent in after-market trading yesterday evening after the developer posted positive data for its dose-ranging, mid-stage trial of its experimental gout
Ardea cuts half its workforce
Just one week after inking a $407 million pact with Bayer--which included a $35 million up-front payment--San Diego-based Ardea Biosciences says it's cutting 47 percent of its workforce. The company
Ardea inks $407M cancer drug pact with Bayer
San Diego-based Ardea Biosciences is pocketing a $35 million upfront payment and stands to earn another $372 million in milestones from a cancer drug development pact that it struck with Bayer
Ardea touts IIa data
San Diego-based Ardea BioSciences is reporting positive results from its Phase IIa proof-of-concept study for an experimental HIV therapy. "RDEA806's robust antiviral potency, combined with its
